Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sofinnova Raises €333m For European Biotech Fund

Venture Capital Firm’s Funds Worth €2bn

Executive Summary

Global investors back Paris-headquartered Sofinnova to recoup investment in life science start-ups.

You may also be interested in...



LSP Closes Mega Life Sciences Fund For Europe, But US Still Way Ahead

A new life sciences fund, LSP 6, is one of the largest fundraisings in Europe in the sector, and will invest in around 15-to-18 pharma or medtech companies.

Breath Therapeutics Snapped Up Post Series A By Specialty Company Zambon

Italy’s privately held Zambon could pay up to 500m to bulk up its respiratory products pipeline, producing a nice return for Breath Therapeutics’ syndicate of European investors.

J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value

In this tale of two companies, it's the best of times and the best of times. J&J gets immediate value by acquiring Actelion's blockbuster PAH franchise and its late-stage pipeline, while its stake in an Actelion spinout offers longer-term potential.

Topics

Related Companies

UsernamePublicRestriction

Register

SC126049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel